{"content_type":"Blog post","title":"Johnson \u0026 Johnson names awardees in the Data \u0026 AI Fueling R\u0026D of Tomorrow QuickFire Challenge: Singapore \u0026 Beyond","sub_title":null,"cover_image":"https:\/\/juniverseadmin.jnjinnovation.com\/sites\/default\/files\/Blog-post\/Data%20Science%20Awardee%20Media%20Blog.jpg","slider_image":null,"another_slider_image":null,"brightcove_account":"3198958923001","brightcove_player":"9Z7fsGThCO","use_video_as_the_header":false,"new_blog_layout":false,"header_video":null,"tags":[],"focus_area":["Data Science","Innovation","Innovation Challenges"],"region":"Asia Pacific","published_date":"2026-07-20","highlighted_text":[],"author_name":null,"author_nid":null,"meta_tags":null,"news_detail_url":null,"body":{"body":[{"paragraph_type":"text","text":[{"value":"\u003Cp\u003E\u003Cspan\u003E\u003Cstrong\u003EJuly 20, 2026\u0026nbsp;\u003C\/strong\u003E\u2013 Today, Johnson \u0026amp; Johnson announced that\u003Cstrong\u003E\u0026nbsp;ChemT Biotechnology, Hill Research, Prima Mente,\u0026nbsp;\u003C\/strong\u003Eand\u0026nbsp;\u003Cstrong\u003EWaypoint Bio\u0026nbsp;\u003C\/strong\u003Ehave been selected as the awardees of the\u0026nbsp;\u003C\/span\u003E\u003Ca href=\u0022https:\/\/jnjinnovation.com\/innovation-challenges\/Data-AI-Fueling-RnD-of-Tomorrow-QuickFire-Challenge-Singapore-Beyond\u0022\u003E\u003Cspan\u003EData \u0026amp; AI Fueling R\u0026amp;D of Tomorrow QuickFire Challenge: Singapore \u0026amp; Beyond\u003C\/span\u003E\u003C\/a\u003E\u003Cspan\u003E.\u003C\/span\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cspan\u003EInnovators around the world with a demonstrated interest in leveraging the Singapore ecosystem were invited to submit their novel AI\/ML innovation strategies and approaches to augmented science with the potential to transform drug discovery and research.\u0026nbsp;\u003C\/span\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cspan\u003EThese four awardees are being recognized for their potentially groundbreaking solutions:\u003C\/span\u003E\u003C\/p\u003E\u003Cdiv style=\u0022padding-left:90px;\u0022\u003E\u003Cp\u003E\u003Ca href=\u0022https:\/\/www.chemtbio.com\/\u0022 target=\u0022_blank\u0022\u003E\u003Cspan\u003E\u003Cstrong\u003EChemT Biotechnology\u003C\/strong\u003E\u003C\/span\u003E\u003C\/a\u003E\u003Cspan\u003E: ChemT\u0026nbsp;Biotechnology built a virtual cell for biomanufacturing aimed to operate as a digital twin making the cellular \u201cblack box\u2019 predictable and controllable to enable target discovery, AI-designed drugs for cells and AI agents for cell engineering.\u003C\/span\u003E\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022https:\/\/www.hillresearch.ai\/\u0022 target=\u0022_blank\u0022\u003E\u003Cspan\u003E\u003Cstrong\u003EHill Research\u003C\/strong\u003E\u003C\/span\u003E\u003C\/a\u003E\u003Cspan\u003E:\u003Cstrong\u003E\u0026nbsp;\u003C\/strong\u003EHill Research developed TriClick\u2122,\u0026nbsp;an agentic AI infrastructure that focuses on automating clinical biometrics workflows with transparent, traceable outputs, reducing programming burden and accelerating drug development timelines.\u003C\/span\u003E\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022https:\/\/www.primamente.com\/\u0022 target=\u0022_blank\u0022\u003E\u003Cspan\u003E\u003Cstrong\u003EPrima Mente\u003C\/strong\u003E\u003C\/span\u003E\u003C\/a\u003E\u003Cspan\u003E:\u0026nbsp;\u0026nbsp;Prima Mente is focused on building multi-omic biological foundation models to decode complex diseases and identify novel therapeutic targets.\u003C\/span\u003E\u003C\/p\u003E\u003Cp\u003E\u003Ca href=\u0022https:\/\/www.waypointbio.com\/\u0022 target=\u0022_blank\u0022\u003E\u003Cspan\u003E\u003Cstrong\u003EWaypoint Bio\u003C\/strong\u003E\u003C\/span\u003E\u003C\/a\u003E\u003Cspan\u003E: Waypoint Bio leverages spatial biology and \u003C\/span\u003E\u003Cem\u003E\u003Cspan\u003Ein vivo\u003C\/span\u003E\u003C\/em\u003E\u003Cspan\u003E perturbation screening to generate training data for AI-driven virtual disease models and drug discovery.\u003C\/span\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cp\u003E\u003Cspan\u003EThe awardees will receive grant funding from a combined total pool of $400,000 and mentorship from experts across Johnson \u0026amp; Johnson.\u003C\/span\u003E \u003Cspan\u003ESelect awardees may also receive JLABS Singapore membership.\u003Csup\u003E*\u003C\/sup\u003E\u003C\/span\u003E\u003C\/p\u003E\u003Cdiv class=\u0022foot\u0022 style=\u0022font-size:.45em;line-height:2;\u0022\u003E\u003Cp\u003E\u003Cem\u003E\u003Cspan\u003E*Subject to terms and conditions of applicable QuickFire Challenge and execution of an award agreement\u003C\/span\u003E\u003C\/em\u003E\u003Cspan\u003E\u0026nbsp;\u003C\/span\u003E\u003C\/p\u003E\u003C\/div\u003E\u003Cp\u003E\u003Cspan\u003E\u003Cstrong\u003EAbout Johnson \u0026amp; Johnson\u0026nbsp;\u003C\/strong\u003E\u003C\/span\u003E\u003C\/p\u003E\u003Cp\u003E\u003Cspan\u003EJohnson \u0026amp; Johnson works across the innovative medicine and medical technology sectors to accelerate early-stage, transformational solutions by catalyzing the best ideas, wherever they are in the world. We do this by harnessing our deep scientific capabilities coupled with a wide range of tools, including customized deal structures, company creation, incubation and startup services, capital investments and other innovative business models that aim to meet the diverse needs of entrepreneurs, scientists, and emerging companies. Our goal is to help life science and health technology innovations thrive through collaboration and partnership with the global ecosystem, so that together we can change the trajectory of human health. Meet our passionate team of science and technology experts and learn how to collaborate with us at\u0026nbsp;\u003C\/span\u003E\u003Ca href=\u0022http:\/\/www.jnjinnovation.com\u0022\u003E\u003Cspan\u003Ewww.jnjinnovation.com\u003C\/span\u003E\u003C\/a\u003E\u003Cspan\u003E.\u003C\/span\u003E\u003C\/p\u003E","format":"full_html"}]}]},"related_news":[{"title":"Introducing Mike Wong: new head of JLABS Singapore","nid":"145178","cover_image":"https:\/\/juniverseadmin.jnjinnovation.com\/sites\/default\/files\/Blog-post\/CoverImage_MikeBlog%202.png","slider_image":null,"another_slider_image":null,"brightcove_account":"3198958923001","header_video":null,"news_detail_url":null,"focus_area":["J\u0026J Leadership","Innovation"],"region":"Asia Pacific","published_date":"2026-09-23","author_name":null,"author_nid":null,"news_type":"blog_post","brightcove_player":"9Z7fsGThCO"},{"title":"JLABS Shanghai welcomes new site head: an interview with Silvia Chen","nid":"145174","cover_image":"https:\/\/juniverseadmin.jnjinnovation.com\/sites\/default\/files\/Blog-post\/CoverImage_Silvia3.png","slider_image":null,"another_slider_image":null,"brightcove_account":"3198958923001","header_video":null,"news_detail_url":null,"focus_area":["Innovation"],"region":"Asia Pacific","published_date":"2026-09-08","author_name":null,"author_nid":null,"news_type":"blog_post","brightcove_player":"9Z7fsGThCO"},{"title":"How Johnson \u0026 Johnson and a Korean biotech startup are rewriting the rules of neuroscience together","nid":"145177","cover_image":"https:\/\/juniverseadmin.jnjinnovation.com\/sites\/default\/files\/Blog-post\/Prazer%20Therapeutics%20Blog%20Cover%20Image%20for%20Website.png","slider_image":null,"another_slider_image":null,"brightcove_account":"3198958923001","header_video":null,"news_detail_url":null,"focus_area":["Neuroscience","Discovery Product Development \u0026 Supply","Innovation","Venture Investments"],"region":"Global","published_date":"2026-09-17","author_name":null,"author_nid":null,"news_type":"blog_post","brightcove_player":"9Z7fsGThCO"},{"title":"The value of coming together: biotech CEO reflections from the JLABS EMEA CEO Summit","nid":"145176","cover_image":"https:\/\/juniverseadmin.jnjinnovation.com\/sites\/default\/files\/Blog-post\/CEO%20Reflections%20-%20cover.png","slider_image":null,"another_slider_image":null,"brightcove_account":"3198958923001","header_video":null,"news_detail_url":null,"focus_area":["J\u0026J Leadership","Innovation"],"region":"EMEA","published_date":"2026-09-10","author_name":null,"author_nid":null,"news_type":"blog_post","brightcove_player":"9Z7fsGThCO"},{"title":"Beyond the cheque: rethinking the role of pharma in building breakthrough biotechs","nid":"145175","cover_image":"https:\/\/juniverseadmin.jnjinnovation.com\/sites\/default\/files\/Blog-post\/IMM%20VC%20Blog%20-%20final_2.png","slider_image":null,"another_slider_image":null,"brightcove_account":"3198958923001","header_video":null,"news_detail_url":null,"focus_area":["Immunology","J\u0026J Leadership","Innovation","Venture Investments","Other"],"region":"EMEA","published_date":"2026-09-09","author_name":null,"author_nid":null,"news_type":"blog_post","brightcove_player":"9Z7fsGThCO"}]}